Grifols (GIFLF) Prepaid Assets (2009 - 2025)
Grifols' (GIFLF) quarterly Prepaid Assets came in at $75.7 million in Q4 2025, down 1.66% on a YoY basis from $76.9 million in Q4 2024, and down 1.66% quarter-over-quarter from $76.9 million in Q4 2024.
Analysis
Grifols (GIFLF) Prepaid Assets (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Prepaid Assets for 17 consecutive years, with $75.7 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Prepaid Assets fell 1.66% year-over-year to $75.7 million; the trailing twelve-month figure through Dec 2025 stood at $75.7 million (down 1.66% YoY), and the FY2025 full-year result was $73.4 million, down 4.55% from the prior year.
- Prepaid Assets declined to $75.7 million in Q4 2025 per GIFLF's latest filing, from $76.9 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $84.4 billion in Q4 2022 and bottomed at $75.7 million in Q4 2025.
- Historically, Prepaid Assets has averaged $31.6 billion across 5 years, with a median of $79.6 million in 2023.
- The sharpest annual moves came in 2021 and 2023: Prepaid Assets surged 118706.04% in 2021, then sank 99.91% in 2023.
- Over 5 years, Prepaid Assets stood at $73.3 billion in 2021, then gained by 15.07% to $84.4 billion in 2022, then tumbled by 99.91% to $79.6 million in 2023, then slipped by 3.29% to $76.9 million in 2024, then slipped by 1.66% to $75.7 million in 2025.
- According to Business Quant data, Prepaid Assets over the past three periods registered $75.7 million, $76.9 million, and $79.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 75.66 Mn |
| Dec 31, 2024 | 76.94 Mn |
| Dec 31, 2023 | 79.56 Mn |
| Dec 31, 2022 | 84.35 Bn |
| Dec 31, 2021 | 73.30 Bn |
| Dec 31, 2020 | 61.70 Mn |
| Sep 30, 2020 | 51.12 Mn |
| Mar 31, 2020 | 50.70 Mn |
| Dec 31, 2019 | 64.32 Mn |
| Sep 30, 2019 | 81.73 Mn |
| Mar 31, 2019 | 24.58 Mn |
| Dec 31, 2018 | 48.33 Mn |
| Sep 30, 2018 | 74.37 Mn |
| Jun 30, 2018 | 42.14 Mn |
| Mar 31, 2018 | 37.36 Mn |
| Dec 31, 2017 | 38.09 Mn |
| Jun 30, 2017 | 28.72 Mn |
| Dec 31, 2016 | 52.18 Mn |
| Sep 30, 2016 | 34.73 Mn |
| Jun 30, 2016 | 29.34 Mn |